Loading…
www.mysteroidsmarket.com was cited for selling unapproved and misbranded drugs, specifically Schedule II stimulants and benzodiazepines, to U.S. consumers via the internet in violation of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The FDA identified critical compliance failures including the introduction of unapproved new drugs into interstate commerce without required regulatory authorization and the misbranding of controlled substances without proper labeling or prescriber oversight. The enforcement action emphasized the significant public health risk posed by these drugs' high potential for abuse, diversion, and polysubstance use patterns, particularly among young adults and college students, as well as the association with overdose deaths when combined with other substances.